Clinical trial Recruiting at 8 sites Interventional Ages 18 to 80

Using 20% albumin with Ringer's lactate during cytoreductive surgery and HIPEC.

Official title: Evaluation de l'efficacité du Remplissage Vasculaire Par de l'ALBUmine Humaine 20% + Ringer Lactate comparé au Ringer Lactate Seul Chez Les Patients opérés Par cytoréduction Avec CHimiothérapie Intrapéritonéale hyPerthermique

Run by Assistance Publique - Hôpitaux de Paris · NCT06351475 · Data updated 2026-11-12

This study will test whether adding 20% albumin to Ringer's lactate during cytoreductive surgery with HIPEC for adults with peritoneal carcinomatosis reduces the need for crystalloid fluids and improves postoperative outcomes.

More Postoperative Complications trials

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment140 (estimated)
SponsorAssistance Publique - Hôpitaux de Paris
Academic / other
Drugs / interventionschemotherapy
Locations8 sites (Lyon and 7 other locations)
StatusRecruiting
StartedSeptember 3, 2025
Main results expectedOctober 2027
Study endsOctober 2027
Registry record updatedSeptember 29, 2026
Trial IDNCT06351475 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–75 with peritoneal carcinomatosis scheduled for cytoreductive surgery with HIPEC who are medically fit for major surgery and do not have conditions that affect albumin levels are the ideal candidates.

Probably not a fit

Patients over 75, those with severe hypoalbuminemia, liver cirrhosis, nephrotic syndrome, significant cardiac or pulmonary disease, or large symptomatic ascites are unlikely to benefit or are excluded from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional trial compares intraoperative administration of concentrated 20% albumin combined with Ringer's lactate versus Ringer's lactate alone during cytoreductive surgery with HIPEC. The albumin arm is intended to reduce the total crystalloid volume given during the procedure, and perioperative fluid balance and postoperative complications will be recorded. Eligible adults (18–75) planned for CRS with HIPEC and affiliated with French health insurance will be enrolled, while patients with severe hypoalbuminemia, significant liver or kidney disease, reduced cardiac function, or high pulmonary risk are excluded. The protocol is carried out at participating centers in Paris and Montpellier.

Why it matters

Potential benefit: If successful, adding 20% albumin could lower crystalloid requirements and reduce fluid-related postoperative complications after CRS with HIPEC.

How similar studies have gone: Albumin has been widely studied in critically ill patients with mixed results, while intraoperative use during major oncologic procedures like CRS with HIPEC has not been well tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male and female patients aged 18 years old and older
* Planned cytoreductive surgery with HIPEC for peritoneal carcinomatosis (from gynaecological or digestive origin)
* Patient volunteer for the study and provided written informed consent
* Patient affiliated to the French Health Insurance

Exclusion Criteria:

* Adults \>75 years old
* Functional status rendering the patient ineligible for cytoreduction with CHIP (ECOG \> 2 or Karnofsky index \< 75)
* Pre-existing preoperative conditions affecting albuminemia (hepatic cirrhosis, nephrotic syndrome, exudative enteropathy, malnutrition)
* Severe preoperative hypoalbuminemia (albuminemia \< 20 g/L)
* History of chronic left heart failure with reduced left ventricular ejection fraction (left ventricular ejection fraction \< 40%)
* Patients at high risk of perioperative and postoperative pulmonary complications (atelectasis, significant pleural effusions)
* Significant ascites with preoperative respiratory repercussions
* Uncontrolled diabetes (HbA1c \> 8.5%)
* Allergy to exogenous human albumin and its excipients.
* Contraindication to the administration of Ringer's lactate (history of allergy)
* Hyperkalemia \> 6.0 mmol/L
* Hypercalcemia (total calcium \> 2.60 mmol/L)
* Chronic use of digitalis and hyperkalemic diuretics
* Pregnancy, breastfeeding
* Known preoperative renal failure (GFR \< 30 mL/min/1.73m2 or extrarenal purification)
* Recent brain trauma \< 6 months (traumatic, ischemic, or hemorrhagic)
* Participation in another interventional study involving human subjects or being in the exclusion period following a previous study involving human subjects, if applicable
* Patient deprived of liberty
* Patient under guardianship or curatorship

Where it's running

  • Hôpital Lyon Sud Pierre Bénite
    Lyon, France
    Recruiting
  • Institut régional du Cancer de Montpellier
    Montpellier, France
    Recruiting
  • La Pitié Salpetriere hospital
    Paris, France
    Recruiting
  • Lariboisière hospital
    Paris, France
    Recruiting
  • Saint Louis hospital
    Paris, France
    Recruiting
  • Robert Debré hospital
    Reims, France
    Recruiting
Show 2 more locations
  • Hôpital Hautepierre / UIC ARMO
    Strasbourg, France
    Recruiting
  • Gustave Roussy Institute
    Villejuif, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.